神奈川県立がんセンターは、神奈川県横浜市旭区にある医療機関。地方独立行政法人神奈川県立病院機構が運営する病院である。都道府県がん診療連携拠点病院に指定されている。 2013年11月2日に新病院が開院し、2015年12月15日に重粒子線治療装置の治療を開始した。

During the past decade, Kanagawa cancer center conducted 79 clinical trials. In the 10-year time frame, 79 clinical trials started and 21 clinical trials were completed, i.e. on average, 26.6% percent of trials that started reached the finish line to date. In the past 5 years, 47 clinical trials started and 20 clinical trials were completed. i.e. 42.6% of trials that started reached the finish line.

Out of the total clinical trials conducted in "Kanagawa cancer center" #1 sponsor was "Pfizer" with 9 trials, followed by "Amgen" with 6 trials sponsored, "EMD Serono Research & Development Institute, Inc." with 6 trials sponsored, "Incyte Corporation" with 6 trials sponsored and "Eli Lilly and Company" with 6 trials sponsored. Other sponsors include 51 different institutions and companies that sponsored additional 38 trials in total.

In terms of collaborators to trials, out of the total clinical trials conducted in "Kanagawa cancer center" #1 collaborator was "Merck KGaA, Darmstadt, Germany" with 8 trials as a collaborator, "Eli Lilly and Company" with 5 trials as a collaborator, "Merck Sharp & Dohme LLC" with 5 trials as a collaborator, "AstraZeneca" with 4 trials as a collaborator and "Japan Agency for Medical Research and Development" with 2 trials as a collaborator. Other collaborators include 26 different institutions and companies that were collaborators in the rest 30 trials.

According to Clinical.Site data, the most researched conditions in "Kanagawa cancer center" are "Carcinoma, Non-Small-Cell Lung" (4 trials), "Colorectal Cancer" (4 trials), "Gastric Cancer" (4 trials), "Breast Cancer" (3 trials) and "Breast Neoplasms" (3 trials). Many other conditions were trialed in "Kanagawa cancer center" in a lesser frequency.

Most popular intervention types in "Kanagawa cancer center" are "Drug" (81 trials), "Other" (4 trials), "Procedure" (4 trials), "Biological" (3 trials) and "Radiation" (2 trials). Other intervention types were less common.

The name of intervention was led by "Placebo" (13 trials), "Cisplatin" (9 trials), "Gemcitabine" (9 trials), "Pembrolizumab" (8 trials) and "Carboplatin" (7 trials). Other intervention names were less common.

The vast majority of trials in "Kanagawa cancer center" are 80 trials for "All" genders and 7 trials for "Female" genders.

Currently, there are NaN active trials in "Kanagawa cancer center". undefined are not yet recruiting, 28 are recruiting, 30 are Active, not recruiting, and undefined are Enrolling by invitation. In total, there were 28 completed trials in Kanagawa cancer center, undefined suspended trials, and 1 terminated clinical trials to date.

Out of the total trials that were conducted in Kanagawa cancer center, 16 "Phase 1" clinical trials were conducted, 20 "Phase 2" clinical trials and 49 "Phase 3" clinical trials were conducted as well. "Phase 4" trials included 0 trials, and there were also 1 trials that are defined as “Not Applicable".

Kanagawa cancer center has several departments that took part in Clinical trials: "Kanagawa Children's Medical Center" - 18 trials, "Kanagawa Cancer Center" - 5 trials, "Kanagawa Cardiovascular and Respiratory Center" - 39 trials, "Kanagawa Children's Medical Center(NW)" - 2 trials